Podcast
The Long Run with Luke Timmerman
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
- Science chart
- #137
- Episodes
- 211
- Releases
- Every two weeks
- Typical length
- 1 hr 9 min
- On air since
- 2017
- Latest episode
- 14 hours ago
Episodes
211 episodes, newest first
-
1 hr 4 min
Ep213: Daphne Koller on The Moment in AI Drug Discovery
Show notes
Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.
-
1 hr 15 min
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Show notes
Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.
-
1 hr 7 min
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Show notes
Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
-
1 hr 4 min
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Show notes
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
-
1 hr 36 min
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Show notes
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
-
1 hr 7 min
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Show notes
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
-
1 hr 18 min
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Show notes
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
-
1 hr 7 min
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Show notes
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
-
1 hr 8 min
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Show notes
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
-
1 hr 7 min
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Show notes
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
-
1 hr 12 min
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Show notes
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
-
1 hr 8 min
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Show notes
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
-
1 hr 9 min
Ep201: Jeremy Levin on Biotech in the Balance
Show notes
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
-
1 hr 14 min
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
Show notes
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
-
1 hr 10 min
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Show notes
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
-
1 hr 17 min
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Show notes
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
-
1 hr 17 min
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Show notes
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
-
1 hr 3 min
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Show notes
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
-
1 hr 6 min
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Show notes
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
-
1 hr 9 min
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
Show notes
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
On these lists
The Long Run with Luke Timmerman is one of the shows picked out on each of these
More in Science
Placed highest on Apple Podcasts' Science chart right now
